BioXcel Therapeutics To Hold Virtual KOL Roundtable On February 27 Highlighting ~100M Annual Alzheimer's Agitation Episodes And Lack Of FDA-Approved Treatments

Discussion will focus on the high unmet need and the lack of FDA-approved treatment options associated with acute agitation episodes in Alzheimer's dementia

Large patient population affected by Alzheimer's agitation, with approximately ~100 million annual episodes1

KOL Roundtable to be held on Friday, February 27, at 2:00 p.m. EST